Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Target Price at $15.00

Shares of Nkarta, Inc. (NASDAQ:NKTX) have been given an average rating of “Buy” by the seven brokerages that are covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $15.00.

A number of research analysts recently commented on the company. RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Needham & Company LLC lowered their price target on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Mizuho lowered their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. HC Wainwright decreased their price objective on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Finally, Rodman & Renshaw began coverage on Nkarta in a report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price objective on the stock.

Nkarta Trading Down 0.8 %

NASDAQ NKTX opened at $2.47 on Friday. The stock’s 50 day moving average is $2.52 and its 200 day moving average is $4.18. Nkarta has a 12 month low of $2.08 and a 12 month high of $16.24. The stock has a market cap of $174.31 million, a PE ratio of -1.31 and a beta of 0.85.

Insider Transactions at Nkarta

In related news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the sale, the chief executive officer now owns 319,859 shares in the company, valued at approximately $703,689.80. This represents a 5.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 8.70% of the company’s stock.

Institutional Trading of Nkarta

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in Nkarta by 252.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company’s stock valued at $4,806,000 after acquiring an additional 761,349 shares during the last quarter. Franklin Resources Inc. bought a new position in Nkarta in the 3rd quarter valued at $151,000. Barclays PLC grew its position in Nkarta by 161.4% in the 3rd quarter. Barclays PLC now owns 232,566 shares of the company’s stock valued at $1,051,000 after acquiring an additional 143,608 shares during the last quarter. Geode Capital Management LLC grew its position in Nkarta by 3.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock valued at $5,294,000 after acquiring an additional 33,927 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Nkarta in the 3rd quarter valued at $223,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.